Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 24 2018 - 4:55PM
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf,
allogeneic T-cell immunotherapy company developing novel treatments
for patients with cancer, autoimmune and viral diseases, today
reported the grant of inducement awards to Renu Vaish, Senior Vice
President, Global Regulatory Affairs, effective as of September 24,
2018.
The compensation committee of Atara's board of directors granted
Ms. Vaish a stock option to purchase 65,000 shares of Atara’s
common stock, and restricted stock units to acquire 22,500 shares
of Atara’s common stock. The stock option and restricted stock
units were granted as an inducement material to Ms. Vaish entering
into employment with the Company in accordance with Nasdaq Listing
Rule 5635(c)(4).
The stock option has a seven-year term and an exercise price of
$40.70, equal to the per share closing price of Atara's common
stock as reported by Nasdaq on September 24, 2018. The awards vest
over four years, with 25% vesting on the first anniversary of the
grant date and the remainder vesting over the following three
years, assuming the employee is continuously employed by Atara as
of such vesting dates.
Atara is providing this information in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.Atara
Biotherapeutics, Inc. (@Atarabio) is a leading off-the-shelf,
allogeneic T-cell immunotherapy company developing novel treatments
for patients with cancer, autoimmune and viral diseases. Atara’s
most advanced T-cell immunotherapy, tab-cel™ (tabelecleucel), is in
Phase 3 development for patients with Epstein-Barr virus associated
post-transplant lymphoproliferative disorder (EBV+ PTLD), as well
as other EBV associated hematologic and solid tumors, including
nasopharyngeal carcinoma (NPC). Atara is also developing T-cell
immunotherapies targeting EBV antigens believed to be important for
the potential treatment of multiple sclerosis (MS). Atara's
pipeline also includes next generation chimeric antigen receptor
T-cell (CAR T) immunotherapies for patients with hematologic and
solid tumors, autoimmune and viral diseases. The company was
founded in 2012 and is headquartered in South San Francisco,
California.
INVESTOR & MEDIA CONTACTS:
Investors:John Craighead, Atara
Biotherapeutics650-410-3012jcraighead@atarabio.com
Steve Klass, Burns McClellan212-213-0006
x331sklass@burnsmc.com
Media:Nancie Steinberg, Burns
McClellan212-213-0006 x318nsteinberg@burnsmc.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Oct 2023 to Oct 2024